Buy Incyte (INCY) on Weakness - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Incyte (INCY) IDO Patient Count Worries Are A "Nothing Burger" - Barclays
June 5, 2017 4:13 PM EDTBarclays maintains Overweight on Incyte (NASDAQ: INCY) price target of $180.00.
Analyst Dr. Geoff Meacham continues to holds INCY scientific and clinical leadership team in high regard and says it is very common to see different numbers of evaluable patients based upon exposure... More
